ProCE Banner Activity

Low-Dose Dasatinib for Newly Diagnosed CML: Long-term Follow-up Outcomes

Slideset Download
Conference Coverage

After 5 years of follow-up, low-dose dasatinib at 50 mg daily continued to be both effective and safe in newly diagnosed CML-CP.

Released: December 17, 2022

Expiration: December 16, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen